Brief: Medexus Announces New License Deal For Topical Terbinafine

Medexus Pharmaceuticals

22/03/2023 11:27

March 22 (Reuters) - Medexus Pharmaceuticals Inc
 MDP.TO :
    * MEDEXUS ANNOUNCES NEW LICENSE DEAL FOR TOPICAL TERBINAFINE
    * MEDEXUS PHARMACEUTICALS INC - SECURED CANADIAN RIGHTS TO
COMMERCIALIZE TERBINAFINE HYDROCHLORIDE NAIL LACQUER SUPPLIED BY
POLICHEM
    * MEDEXUS PHARMACEUTICALS INC - HAS AGREED TO SPONSOR NEW
DRUG
SUBMISSION SEEKING HEALTH CANADA APPROVAL OF TOPICAL TERBINAFINE
NAIL LACQUER
    * MEDEXUS PHARMACEUTICALS INC - LONG-TERM LICENSE AGREEMENT
PROVIDES FOR LOW UPFRONT PAYMENT
    * MEDEXUS PHARMACEUTICALS - IF APPROVED BY HEALTH CANADA, TO
PAY
POLICHEM QUARTERLY LOW DOUBLE-DIGIT PERCENTAGE ROYALTY ON NET
SALES OF PRODUCT
    * MEDEXUS PHARMACEUTICALS -  LONG-TERM LICENSE AGREEMENT
ALSO
PROVIDES FOR FOUR SALES-BASED MILESTONE PAYMENTS, WHICH LIMITS
MEDEXUS'S INITIAL OUTLAY

Source text for Eikon:  ID:nGNX3C4GBn 
Further company coverage:  MDP.TO 

 ((Reuters.Briefs@thomsonreuters.com;))